Protagenic Therapeutics Inc (PTIX)

$3.85 +0.04 (1.05%)
Market Cap 2.24M
Revenue (ttm) 0.00
Net Income (ttm) -5.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 684,100
Avg Vol 2,538,685
Day's Range N/A - N/A
Shares Out 589,000.00
Stochastic %K 1%
Beta 0.28
Analysts Strong Buy
Price Target $4.00

Latest News on PTIX

Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity

May 21, 2025, 9:15 AM EDT - 10 days ago

Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity

Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher

May 19, 2025, 1:40 PM EDT - 12 days ago

Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher

Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders

May 19, 2025, 7:43 AM EDT - 12 days ago

Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders

Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split

Apr 29, 2025, 4:00 PM EDT - 4 weeks ago

Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split

Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

Nov 5, 2024, 8:12 AM EST - 7 months ago

Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

Oct 29, 2024, 9:27 AM EDT - 7 months ago

Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial

May 1, 2024, 8:38 AM EDT - 1 year ago

Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial

Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit

Apr 17, 2024, 8:42 AM EDT - 1 year ago

Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit

Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript

Apr 1, 2024, 9:32 PM EDT - 1 year ago

Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Apr 1, 2024, 4:20 PM EDT - 1 year ago

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders

Mar 27, 2024, 8:42 AM EDT - 1 year ago

Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders

Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call

Mar 25, 2024, 5:00 PM EDT - 1 year ago

Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call

Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice

Mar 21, 2024, 8:41 AM EDT - 1 year ago

Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice

Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders

Feb 13, 2024, 8:30 AM EST - 1 year ago

Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders

Protagenic Therapeutics Announces Date of Annual Shareholder Meeting

Oct 13, 2023, 9:00 AM EDT - 1 year ago

Protagenic Therapeutics Announces Date of Annual Shareholder Meeting

Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114

Sep 26, 2023, 8:18 AM EDT - 1 year ago

Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114

Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split

Mar 22, 2023, 12:55 PM EDT - 2 years ago

Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split

Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th

Apr 26, 2022, 8:15 AM EDT - 3 years ago

Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th

Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update

Nov 16, 2021, 9:58 AM EST - 3 years ago

Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update

Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET

Aug 30, 2021, 9:15 AM EDT - 4 years ago

Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET

Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update

Aug 17, 2021, 7:45 AM EDT - 4 years ago

Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update

Protagenic Therapeutics To Start Clinical Trials For Depression Candidate By 2021 End

Jul 26, 2021, 6:31 AM EDT - 4 years ago

Protagenic Therapeutics To Start Clinical Trials For Depression Candidate By 2021 End

Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial

Jul 23, 2021, 4:21 PM EDT - 4 years ago

Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial

Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET

Jul 6, 2021, 6:17 AM EDT - 4 years ago

Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET

Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th

Jun 16, 2021, 9:15 AM EDT - 4 years ago

Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th

Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq

Apr 29, 2021, 3:06 PM EDT - 4 years ago

Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq

Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering

Apr 26, 2021, 8:58 PM EDT - 4 years ago

Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering